Netflix To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Friday
Portfolio Pulse from Avi Kapoor
Top Wall Street analysts have updated their price targets and ratings for several major companies, including Netflix, Robinhood, Intuitive Surgical, Banner Corporation, D.R. Horton, Sage Therapeutics, M&T Bank, Domino’s Pizza, Arm Holdings, and JPMorgan Chase. Notable changes include Evercore ISI Group boosting Netflix's price target to $710 and Morgan Stanley upgrading Arm Holdings to Overweight with a new price target of $190.
July 19, 2024 | 1:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley boosted Arm Holdings' price target from $107 to $190, upgrading the stock from Equal-Weight to Overweight. Arm Holdings shares closed at $158.33 on Thursday.
The significant increase in price target and upgrade to Overweight from Morgan Stanley indicate strong positive sentiment for Arm Holdings.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100
POSITIVE IMPACT
Piper Sandler increased Banner Corporation's price target from $51 to $65, maintaining an Overweight rating. Banner shares fell 1.4% to close at $58.49 on Thursday.
The increased price target and maintained Overweight rating from Piper Sandler indicate a positive outlook for Banner Corporation.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
JMP Securities boosted the price target for D.R. Horton from $170 to $210, maintaining a Market Outperform rating. D.R. Horton shares gained 10.1% to close at $173.42 on Thursday.
The significant increase in price target and maintained Market Outperform rating from JMP Securities, along with the recent share price gain, indicate strong positive sentiment for D.R. Horton.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100
POSITIVE IMPACT
Keybanc increased the price target for Robinhood from $23 to $25, maintaining an Overweight rating. Robinhood shares fell 5.6% to close at $22.83 on Thursday.
Despite the recent decline in share price, the increased price target and Overweight rating from Keybanc indicate a positive outlook for Robinhood.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Stifel raised the price target for Intuitive Surgical from $430 to $475, maintaining a Buy rating. Intuitive Surgical shares fell 2.4% to close at $416.14 on Thursday.
The raised price target and maintained Buy rating from Stifel suggest a positive outlook for Intuitive Surgical, despite the recent decline in share price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Evercore ISI Group boosted the price target for Netflix from $700 to $710, maintaining an Outperform rating. Netflix shares declined 0.7% to close at $643.04 on Thursday.
The increase in price target and maintained Outperform rating by Evercore ISI Group is a positive signal for Netflix, suggesting potential for a price rally.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Keefe, Bruyette & Woods increased JPMorgan Chase's price target from $195 to $203, maintaining a Market Perform rating. JPMorgan shares closed at $209.98 on Thursday.
The increased price target but maintained Market Perform rating from Keefe, Bruyette & Woods suggest a neutral outlook for JPMorgan Chase.
CONFIDENCE 75
IMPORTANCE 65
RELEVANCE 100
NEUTRAL IMPACT
Keefe, Bruyette & Woods raised M&T Bank's price target from $170 to $180, maintaining a Market Perform rating. M&T Bank shares closed at $167.38 on Thursday.
The increased price target but maintained Market Perform rating from Keefe, Bruyette & Woods suggest a neutral outlook for M&T Bank.
CONFIDENCE 75
IMPORTANCE 65
RELEVANCE 100
NEGATIVE IMPACT
Wedbush cut Domino’s Pizza's price target from $575 to $510, maintaining an Outperform rating. Domino’s shares closed at $409.04 on Thursday.
The reduced price target but maintained Outperform rating from Wedbush suggest a mixed outlook for Domino’s Pizza.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Mizuho cut Sage Therapeutics' price target from $18 to $16, maintaining a Neutral rating. Sage Therapeutics shares closed at $12.17 on Thursday.
The reduced price target and maintained Neutral rating from Mizuho suggest a negative outlook for Sage Therapeutics.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100